Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples